Abstract 347P
Background
Controversy exists regarding the optimal margin of surgical excision for cutaneous squamous cell carcinoma (cSCC). Japanese clinical practice guidelines for skin cancer (second edition) recommend an excision with a 4–6-mm clinical margin for low-risk cSCC and >6-mm clinical margin for high-risk cSCC. However, it is difficult to follow this guideline for all cSCCs because high-risk cSCCs frequently occur on the face or in older patients. The purpose of this study was to investigate the correlation between surgical margin and prognosis in patients with cSCC.
Methods
Patients with cSCC who underwent surgical excision of the primary site between 2011 and 2019 at Saitama Medical University International Medical Center were included in this retrospective observational study. Patients were divided into two groups: group A (standard surgery with guideline-recommended margin) and group B (modified surgery with narrow margin). Overall survival (OS), relapse-free survival (RFS), local recurrence-free survival (LRFS), regional metastasis-free survival (RMFS), and distant metastasis-free survival (DMFS) were compared between the two groups.
Results
A total of 107 patients with cSCC were included in this study: 39 in group A and 68 in group B. There were no significant differences in patient characteristics such as sex, tumor border, and risk factors; age and tumor size differed between groups. There were no statistically significant differences in OS (p=.470), LRFS (p=.631), RMFS (p=.502), and DMFS (p=.475) between the two groups. However, RFS was significantly lower in group A than in group B (p=.049).
Conclusions
This study did not reveal a significant impact of clinical margin on OS in patients with cSCC. Although this conclusion may have been limited by selection bias, excision with narrower margins than those suggested by current guidelines may be appropriate.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract